Semi-automated production of 89Zr-oxalate/89Zr-chloride and the potential of 89Zr-chloride in radiopharmaceutical compounding

Mai Lin; Uday Mukhopadhyay; Gregory J. Waligorski; Julius A. Balatoni; Carlos González-Lepera

doi:10.1016/j.apradiso.2015.11.016

Semi-automated production of ⁸⁹Zr-oxalate/⁸⁹Zr-chloride and the potential of ⁸⁹Zr-chloride in radiopharmaceutical compounding

Mai Lin, Uday Mukhopadhyay, Gregory J. Waligorski, Julius A. Balatoni, Carlos González-Lepera

Nuclear Medicine

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Interest in using ⁸⁹Zr is rapidly increasing for immuno-PET applications due to its unique characteristics and increased availability. The focus of this study was to develop an optimized semi-automated methodology for producing ⁸⁹Zr-oxalate/⁸⁹Zr-chloride, and evaluate the potential application of ⁸⁹Zr-chloride for radiopharmaceutical compounding. The data presented herein will be useful for the production of ⁸⁹Zr-labeled radiopharmaceuticals and their compliance with regulatory issues for both preclinical and clinical use.

Original language	English (US)
Pages (from-to)	317-322
Number of pages	6
Journal	Applied Radiation and Isotopes
Volume	107
DOIs	https://doi.org/10.1016/j.apradiso.2015.11.016
State	Published - Jan 1 2016

Keywords

DFO
PET
Radiopharmaceutical compounding
Remote synthesis module
Semi-automation
Zr

ASJC Scopus subject areas

Radiation

Access to Document

10.1016/j.apradiso.2015.11.016

Cite this

@article{b8a492d451534184be9e2870b073aa41,

title = "Semi-automated production of 89Zr-oxalate/89Zr-chloride and the potential of 89Zr-chloride in radiopharmaceutical compounding",

abstract = "Interest in using 89Zr is rapidly increasing for immuno-PET applications due to its unique characteristics and increased availability. The focus of this study was to develop an optimized semi-automated methodology for producing 89Zr-oxalate/89Zr-chloride, and evaluate the potential application of 89Zr-chloride for radiopharmaceutical compounding. The data presented herein will be useful for the production of 89Zr-labeled radiopharmaceuticals and their compliance with regulatory issues for both preclinical and clinical use.",

keywords = "DFO, PET, Radiopharmaceutical compounding, Remote synthesis module, Semi-automation, Zr",

author = "Mai Lin and Uday Mukhopadhyay and Waligorski, {Gregory J.} and Balatoni, {Julius A.} and Carlos Gonz{\'a}lez-Lepera",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd.",

year = "2016",

month = jan,

day = "1",

doi = "10.1016/j.apradiso.2015.11.016",

language = "English (US)",

volume = "107",

pages = "317--322",

journal = "Applied Radiation and Isotopes",

issn = "0969-8043",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Semi-automated production of 89Zr-oxalate/89Zr-chloride and the potential of 89Zr-chloride in radiopharmaceutical compounding

AU - Lin, Mai

AU - Mukhopadhyay, Uday

AU - Waligorski, Gregory J.

AU - Balatoni, Julius A.

AU - González-Lepera, Carlos

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Interest in using 89Zr is rapidly increasing for immuno-PET applications due to its unique characteristics and increased availability. The focus of this study was to develop an optimized semi-automated methodology for producing 89Zr-oxalate/89Zr-chloride, and evaluate the potential application of 89Zr-chloride for radiopharmaceutical compounding. The data presented herein will be useful for the production of 89Zr-labeled radiopharmaceuticals and their compliance with regulatory issues for both preclinical and clinical use.

AB - Interest in using 89Zr is rapidly increasing for immuno-PET applications due to its unique characteristics and increased availability. The focus of this study was to develop an optimized semi-automated methodology for producing 89Zr-oxalate/89Zr-chloride, and evaluate the potential application of 89Zr-chloride for radiopharmaceutical compounding. The data presented herein will be useful for the production of 89Zr-labeled radiopharmaceuticals and their compliance with regulatory issues for both preclinical and clinical use.

KW - DFO

KW - PET

KW - Radiopharmaceutical compounding

KW - Remote synthesis module

KW - Semi-automation

KW - Zr

UR - http://www.scopus.com/inward/record.url?scp=84947286908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947286908&partnerID=8YFLogxK

U2 - 10.1016/j.apradiso.2015.11.016

DO - 10.1016/j.apradiso.2015.11.016

M3 - Article

C2 - 26595775

AN - SCOPUS:84947286908

SN - 0969-8043

VL - 107

SP - 317

EP - 322

JO - Applied Radiation and Isotopes

JF - Applied Radiation and Isotopes

ER -